Novo Nordisk continues exceptional dividend statistics following 2023 recent stock split

Novo Nordisk, a leading pharmaceutical company based in Denmark, has delivered some impressive dividend statistics for fiscal years 2022 and 2023. Notably, the company achieved over 25 consecutive years of dividend growth, further bolstered by a recent stock split.

Fiscal Year 2022 Highlights

Novo Nordisk declared a dividend of DKK 6.20 per share for fiscal year 2022, reflecting a substantial 19.2% increase compared to the previous fiscal year. This dividend hike demonstrates the company's strong financial performance and commitment to rewarding shareholders.

Fiscal Year 2023 Interim Dividend

In fiscal year 2023, Novo Nordisk announced an interim dividend of DKK 3.00 per share, showcasing an impressive 41.2% increase from the interim dividend in the preceding fiscal year. Novo Nordisk has been a European Dividend Aristocrat for many years now.

Long-Term Growth Metrics

Novo Nordisk's 20-year compound annual growth rate (CAGR) for dividends stands at 19.4%, illustrating a consistent track record of value creation for shareholders over two decades.

The European company's 30-year CAGR is even more remarkable, with a growth rate of +21%, reinforcing its reputation for sustained and robust dividend growth.

Stock Split

Novo Nordisk conducted a stock split recently, which is expected to broaden its investor base by making its shares more accessible and affordable. The ex-date for this 1:2 (two new shares for each old share) stock split was September 13, 2023.

Current Dividend Yield and Annual Dividend in Euros

Novo Nordisk's current dividend yield is 1.1%, offering investors an income-generating opportunity. The company's annual dividend payments, when converted to euros, amount to an impressive €2.855 billion.

These dividend statistics underscore Novo Nordisk's strong financial performance and its dedication to creating value for its shareholders. The recent stock split adds to the company's appeal and reflects its confidence in future growth prospects.

Novo Nordisk A/S is a global healthcare company specializing in diabetes care and pharmaceutical product development, manufacturing, and marketing. The company operates through two segments: diabetes and obesity care, and biopharmaceuticals, offering products like insulin, GLP-1, and therapies for hemophilia, growth hormone, and hormone replacement. With a presence in over 180 countries, it serves through North America and International Operations commercial units.